Penicillamine-induced myositis. Observations and unique features in two patients and review of the literature.
Dermatomyositis developed during treatment with penicillamine in two patients with rheumatoid arthritis. Both were male without a history of penicillin allergy. Eosinophilia was present at the start of their illness, and HLA tissue typing showed the presence of HLA-DR2 in one patient. One patient was retreated with penicillamine and remained asymptomatic after three years of therapy, and the other was able to take penicillamine in a reduced dosage.
D000328:Adult; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001706:Biopsy; D003882:Dermatomyositis / Q000139:chemically induced* / Q000276:immunology; D004802:Eosinophilia / Q000139:chemically induced; D006684:HLA-DR Antigens; D000949:Histocompatibility Antigens Class II / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D009132:Muscles / Q000276:immunology; D010396:Penicillamine / Q000009:adverse effects*
D006684:HLA-DR Antigens; D000949:Histocompatibility Antigens Class II; D010396:Penicillamine